"Mean plasma half-life = 3.4 hours "@en . "Boceprevir is a direct acting protease inhibitor for the treatment of hepatitis C. It also has two isomers in which the S isomer is more active than the R-isomer. FDA approved on May 13, 2011. "@en . "Mean total body clearance (Cl/F) = 161 L/h "@en . . . . "~722 L"@en . "Boceprevir inhibits replication of the hepatitis C virus by binding reversibly to nonstructural protein 3/4a (NS3 and NS4A respectively) serine protease. NS4A is a cofactor that works with NS3 for viral replication. "@en . "Removed via feces (79%) and urine (9%) which suggest some degree of hepatic excretion. "@en . . . . . "Food increases exposure of boceprevir by up to 65% relative to fasting state. However, type of food and time of meal does not affect bioavailability of boceprevir and thus can be taken without regards to food. Tmax = 2 hours; Time to steady state, three times a day dosing = 1 day; Cmax, 400 mg single dose, healthy subject = 557 ng/mL; AUC \u221E, healthy subject = 2020 ng \u00B7 h/mL;"@en . . . "394730-60-0"@en . "Hepatitis C virus, RSV and other RNA/DNA viruses"@en . . "Treatment of chronic hepatitis C genotype 1 in patients that have a compensated liver (as a result of liver diseases like cirrhosis) and are previously untreated or therapy with peginterferon alfa and ribavirin has failed. "@en . . "approved"@en . . . . . "James Lalonde, Tao Li, Jack Liang, Benjamin Mijts, Roger Sheldon, George S.K. Wong, Aleksey Zaks, \"Substantially Stereomerically Pure Fused Bicyclic Proline Compounds and Processes for Preparing Boceprevir.\" U.S. Patent US20120289709, issued November 15, 2012."@en . "# Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/23140245 # Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA: Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/22799589 # Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM: Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012 Apr;26(4):205-10. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/22506260"@en . . "~75%"@en . "SCH 503034"@en . . . . . . "Boceprevir"@en . . . . . . . . . . "Food increases the exposure of boceprevir by up to 65%. However, bioavailability is not affected and thus can be taken without regards to meals."@en . . . . . . . . . . . . "Victrelis"@en .